Fair Value Distribution — percentile bands
26.9% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
5.4%/yr
±4.9% · revenue growth to justify current price
FCF-Based Reverse DCF
8.0%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Q3 beat on revenue (+9% YoY to .0B) driven by Cardiovascular (+14%) and Diabetes (+15%), but GAAP EPS declined to /bin/zsh.89 vs .01 as restructuring ballooned (M) and litigation charges hit (M). Non-...